Go Pro

Crinetics Pharmaceuticals (CRNX) News Today

Crinetics Pharmaceuticals logo
$84.95 0.00 (0.00%)
As of 09/1/2026

Crinetics Pharmaceuticals Latest News

Why Crinetics Stock Soared 99% This Week
Vertex Pharmaceuticals logo displayed on a glass wall in an office lobby with a DNA helix sculpture nearby.
Vertex’s Crinetics Deal Balances Growth with Integration Risk (CRNX)
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

Crinetics Pharmaceuticals Media Mentions By Week

Crinetics Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRNX
News Sentiment

0.71

0.77

Average
Healthcare
News Sentiment

Crinetics Pharmaceuticals News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRNX Articles
This Week

19

6

CRNX Articles
Average Week

Crinetics Pharmaceuticals Trends on MarketBeat

This week vs. last week
Searches
1
-50%
Page Views
2,857
+2%
Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Crinetics Pharmaceuticals dated 9/6/2026.
From Our Partners